#AMJOncology
LightNews LightNews
amjeditor.bsky.social
📊 COVID-19 disrupted cancer patterns, and men were hit harder. National data reveal sharper declines in cancer diagnoses among men than women during the pandemic, altering long-term detection and prevention trends.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #CancerResearch
COVID-19 Altered Cancer Rates Differently for Men and Women
A population-based study found enduring sex differences in cancer incidence after COVID-19, with males and females showing distinct postpandemic patterns across tumor types.
www.emjreviews.com
November 11, 2025 at 5:25 PM
amjeditor.bsky.social
Huge congratulations to Dr. Erika Hamilton, #ASCO2025 Scientific Chair, and #AMJOncology Editorial Board member on her fantastic effort on this year’s program.
May 31, 2025 at 3:21 PM
amjeditor.bsky.social
Why can the same carcinogen lead to different tumors?

New findings suggest inherited genetics influence which driver mutations emerge, how quickly cancer develops, and whether genomic instability occurs.

Read more: www.emjreviews.com/en-us/amj/on...

#AMJOncology #CancerResearch #Genomics
Same Mutagen, Different Tumors: How Genetics Dictate Cancer Risk
Germline genetic background dictates oncogenic driver choice and tumor evolution. Read more to discover how inheritance impacts cancer.
www.emjreviews.com
July 31, 2026 at 3:01 PM
amjeditor.bsky.social
🤖 Artificial neural networks predicted overall and progression-free survival in adults aged 65+ with head and neck cancer after chemoradiation, using standard clinical variables across 19 global centers.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #CancerResearch
AI Outcome Prediction for Chemoradiation in Head and Neck Cancer
Artificial neural networks predicted overall and progression-free survival after chemoradiation in older adults with head and neck cancer, enabling pragmatic risk stratification to inform personalized...
www.emjreviews.com
November 6, 2025 at 8:00 PM
amjeditor.bsky.social
A comprehensive study from Japan reveals that cancer survivors have a significantly elevated risk of cardiovascular mortality, particularly those with specific cancer types.

www.emjreviews.com/en-us/amj/on...

#AMJOncology
@amjreviews.bsky.social
Cancer Survivors in Japan Face Elevated Cardiovascular Mortality Risk
A large population-based study from Japan finds that cancer survivors face a significantly higher risk of death from cardiovascular disease, with risk varying widely by cancer type and CVD subtype.
www.emjreviews.com
May 15, 2025 at 7:35 PM
amjeditor.bsky.social
Standout session at #ASCO25:
ADC 2.0: Discovering the Targets That Will Change the Game, starting with a presentation from Dr. Patricia LoRusso.

Next-gen antibody-drug conjugates are here. New targets, deeper insights, and real-world promise.

#Oncology #ADC #AMJOncology #TranslationalMedicine
June 2, 2025 at 2:58 PM
amjeditor.bsky.social
🚨 Breakthrough at #ASCO25: Inavolisib + palbociclib + fulvestrant improves survival in PIK3CA-mutated HR+/HER2- advanced breast cancer. OS: 34 mo vs 27 mo, PFS: 17.2 mo vs 7.3 mo. A potential new standard of care.

www.emjreviews.com/en-us/amj/on...

@amjreviews.bsky.social
#AMJOncology
Inavolisib-Based Triple Therapy Improves OS in Advanced Breast Cancer: ASCO 2025
Final OS results from INAVO120 show inavolisib plus palbociclib and fulvestrant significantly improves survival, delays chemotherapy, and maintains disease control in PIK3CA-mutated HR+ advanced breas...
www.emjreviews.com
May 31, 2025 at 5:23 PM
amjeditor.bsky.social
New data from #AACR2025 show a steep decline in breast cancer deaths among females aged 20–49. Luminal A and triple-negative types saw the biggest drop. Disparities remain for Black women.

Read the full @amjreviews.bsky.social article here: www.emjreviews.com/en-us/amj/on...
#AMJOncology
Sharp Drop in Young Women’s Breast Cancer Deaths: AACR 2025
New SEER data presented at AACR 2025 reveal a sharp decline in breast cancer mortality among women aged 20 to 49 across all subtypes and racial groups, with major progress seen after 2016.
www.emjreviews.com
May 7, 2025 at 7:21 PM
amjeditor.bsky.social
🌍 Intelligent training could be key to ending cervical cancer. A global study found AI-powered learning tools boost colposcopy accuracy and clinician confidence, helping close training gaps worldwide.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #CervicalCancer #AIinMedicine #WomensHealth
Intelligent Learning Tools Strengthen Global Cervical Cancer Training
A new intelligent digital training tool for colposcopy significantly improved diagnostic accuracy and confidence among clinicians worldwide, accelerating global cervical cancer elimination efforts.
www.emjreviews.com
October 7, 2025 at 4:33 PM
amjeditor.bsky.social
New hope for ES-SCLC: IMforte trial shows improved PFS & OS with lurbinectedin + atezolizumab in 1L maintenance. Results shared at #ASCO25.

📖 www.emjreviews.com/en-us/amj/on...

#AMJOncology
ES-SCLC Maintenance Outcomes From IMforte Trial: ASCO 2025
Phase 3 trial shows lurbinectedin plus atezolizumab significantly improves progression-free and overall survival in ES-SCLC patients receiving first-line maintenance treatment.
www.emjreviews.com
May 31, 2025 at 7:15 PM
amjeditor.bsky.social
🧠 Improving transitions means improving outcomes. New evidence shows care coordination for head and neck cancer patients often falls short, especially between diagnosis, surgery, and radiation therapy. Read more on how teams can bridge the gap.

www.emjreviews.com/en-us/amj/on...

#AMJOncology
Improving Outcomes Through Coordinated Head and Neck Care
A scoping review reveals key gaps in transitions in care among head and neck cancer patients, urging stronger coordination between multidisciplinary teams to improve outcomes.
www.emjreviews.com
October 23, 2025 at 2:54 PM
amjeditor.bsky.social
💊 New data show chemotherapy choice drives acute toxicity in anal cancer care. 5-FU or capecitabine significantly increases diarrhea risk, while cisplatin or radiotherapy alone show lower incidence.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #CancerCare
Chemotherapy Choice Drives Diarrhea Risk in Anal Cancer
Treatment of anal cancer with chemoradiotherapy shows a threefold higher risk of acute diarrhea with 5-FU or capecitabine, while no predictors of late diarrhea were identified.
www.emjreviews.com
September 16, 2025 at 6:09 PM
amjeditor.bsky.social
💊 TAR-200 shows strong responses in BCG-unresponsive bladder cancer, with durable outcomes and a favorable safety profile.

www.emjreviews.com/en-us/amj/on...

#Oncology #Urology #BladderCancer #AMJOncology
TAR-200 Shows Strong Responses in High-Risk Bladder Cancer
TAR-200 monotherapy demonstrated durable complete responses and disease-free survival with favorable safety in patients with BCG-unresponsive high-risk bladder cancer in the phase IIb SunRISe-1 study.
www.emjreviews.com
September 2, 2025 at 5:34 PM
amjeditor.bsky.social
🧴 TNF inhibitors may reduce cancer risk in psoriasis, with no rise in melanoma or blood cancers. Other biologics also show long-term safety signals.

www.emjreviews.com/en-us/amj/de...

#Psoriasis #Dermatology #AMJOncology
TNF Inhibitors Linked to Lower Cancer Risk in Psoriasis
Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic therapies without increased melanoma or hematologic malignancy risk.
www.emjreviews.com
August 13, 2025 at 2:26 PM
amjeditor.bsky.social
📈 Quality of life is being overlooked in early-stage NSCLC research. Almost 50% of TKI and ICI trials don’t report QoL, missing a key measure of patient-centred care in curative treatment settings.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #LungCancer #PatientOutcomes
Patient QoL Often Overlooked in Early-Stage NSCLC Research
A systematic review reveals poor assessment and reporting of health-related quality of life (HRQoL) in early-stage NSCLC trials testing tyrosine kinase and immune checkpoint inhibitors.
www.emjreviews.com
October 12, 2025 at 12:59 PM
amjeditor.bsky.social
🧬 Folinic acid combination may help extend treatment pathways in pancreatic cancer. Research shows patients treated with nanoliposomal irinotecan, fluorouracil, and folinic acid remain eligible for third-line chemotherapy.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #PancreaticCancer
Folinic Acid Combination May Help Extend Options in Pancreatic Cancer
New data show that patients with unresectable pancreatic cancer may benefit from third-line chemotherapy following nanoliposomal irinotecan, fluorouracil, and folinic acid, with prognostic factors gui...
www.emjreviews.com
September 25, 2025 at 2:33 PM
amjeditor.bsky.social
New oral therapy nearly doubles progression-free survival in ESR1-mutated breast cancer, shows results vs. fulvestrant at #ASCO25.

📖 Read more: www.emjreviews.com/en-us/amj/on...

#AMJOncology
New Oral Therapy Doubles PFS in ESR1+ Breast Cancer: ASCO 2025
Vepdegestrant, an oral PROTAC, nearly doubles progression-free survival in ESR1-mutated, ER-positive advanced breast cancer, according to phase 3 VERITAC-2 trial results presented at ASCO 2025.
www.emjreviews.com
May 31, 2025 at 7:11 PM
amjeditor.bsky.social
🎗️🧠 Shoulder ROM tightens: 81% limited 1 month post–breast cancer surgery. Higher risk with age, node removal, total mastectomy.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #BreastCancer #Rehab
Shoulder Joint Range of Motion Falls After Breast Cancer Surgery
Shoulder joint range of motion was limited in over 80% of patients 1 month after breast cancer surgery, with older age, more nodes removed, and total mastectomy increasing risk.
www.emjreviews.com
January 21, 2026 at 5:17 PM
amjeditor.bsky.social
🌏 Survey of 300 oncology professionals highlights key barriers to cancer research in Asia-Pacific: competing demands, funding shortfalls, limited access, and weak infrastructure continue to impede trial capacity.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #CancerResearch
Survey Reveals Key Obstacles to Cancer Research
A cross-sectional survey of oncology professionals in 21 Asia-Pacific countries identified major barriers to clinical cancer research, including funding, infrastructure, and patient access challenges.
www.emjreviews.com
September 23, 2025 at 3:34 PM
amjeditor.bsky.social
🧩 New study finds patients with head and neck cancer facing over five barriers or perioperative adverse effects have drastically lower odds of starting postoperative radiation within 6 weeks.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #HeadAndNeckCancer
Multiple Barriers Delay Radiation for Head and Neck Cancer
Delays in postoperative radiation for head and neck cancer are strongly tied to multiple barriers and poor care coordination, highlighting the urgent need for streamlined patient management.
www.emjreviews.com
September 11, 2025 at 6:50 PM
amjeditor.bsky.social
🚀 #WCLC 2025: DLL3-Directed therapy shows encouraging results in relapsed SCLC. Phase I trial of SHR-4849 reached 59.5% overall response and up to 77.8% at higher doses, without dose-limiting toxicities.

www.emjreviews.com/en-us/amj/re...

#AMJOncology #LungCancerResearch
WCLC 2025: DLL3 Therapy Shows Promise in Relapsed SCLC
A Phase 1 trial of the DLL3-targeted antibody-drug conjugate SHR-4849 shows high response rates and manageable safety in relapsed small cell lung cancer, supporting further clinical development.
www.emjreviews.com
September 9, 2025 at 6:34 PM
amjeditor.bsky.social
⚡ Teamwork Matters, when surgical teams are familiar in urologic oncology, patients recover faster and safer. Up to 40 minutes shaved from OR time, stays drop from 5.3 to 1.94 days, and 30-day readmissions almost halve.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #UrologicCancer
Familiar Surgical Teams Improve Urologic Cancer Outcomes
Familiarity among surgical teams in renal, bladder, and prostate cancer operations leads to shorter procedures, reduced hospital stays, and fewer readmissions, highlighting efficiency gains through co...
www.emjreviews.com
September 4, 2025 at 3:56 PM
amjeditor.bsky.social
🫁 GLP-1 receptor agonists may improve survival in obese patients with lung cancer and enhance immunotherapy efficacy, according to new findings.

www.emjreviews.com/en-us/amj/on...

#LungCancer #Oncology #Immunotherapy #AMJOncology
Obesity-Restricted Benefits of GLP-1 Therapy in Lung Cancer
GLP-1 receptor agonists improved survival outcomes in overweight and obese lung cancer patients and enhanced immunotherapy efficacy, with preclinical evidence suggesting obesity-specific immune modula...
www.emjreviews.com
August 28, 2025 at 2:51 PM
amjeditor.bsky.social
💊 Regular ibuprofen use was linked to a lower risk of endometrial cancer in a large U.S. cohort study, but aspirin offered no protection.

www.emjreviews.com/en-us/amj/on...

#EndometrialCancer #Oncology #AMJOncology
Ibuprofen Emerges as Protective Factor Against Endometrial Cancer
Frequent ibuprofen use, but not aspirin, was linked to a reduced risk of endometrial cancer in a large U.S. cohort study, especially among women with cardiovascular disease.
www.emjreviews.com
August 21, 2025 at 3:58 PM
amjeditor.bsky.social
🧠 New hope in pediatric brain cancer: a nanomedicine breakthrough improves drug delivery across the blood-brain barrier, enhancing treatment potential for children with CNS tumors.

www.emjreviews.com/en-us/amj/on...

#AMJOncology #InfectiousDiseases #PediatricOncology
Nanomedicine Breakthrough Improves Drug Delivery in Pediatric Brain Tumors
Nanomedicine and immunotherapy are redefining pediatric CNS tumor care by overcoming the blood-brain barrier and enabling targeted, less toxic treatment strategies for improved outcomes.
www.emjreviews.com
August 19, 2025 at 5:27 PM